Adverum Biotechnologies, Inc. (ADVM): Price and Financial Metrics


Adverum Biotechnologies, Inc. (ADVM): $1.94

-0.09 (-4.43%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ADVM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 476

in industry

ADVM POWR Grades


  • ADVM scores best on the Value dimension, with a Value rank ahead of 61.42% of US stocks.
  • ADVM's strongest trending metric is Quality; it's been moving up over the last 52 weeks.
  • ADVM's current lowest rank is in the Stability metric (where it is better than 5.77% of US stocks).

ADVM Stock Summary

  • With a price/sales ratio of 26.57, Adverum Biotechnologies Inc has a higher such ratio than 92.3% of stocks in our set.
  • With a year-over-year growth in debt of 341.62%, Adverum Biotechnologies Inc's debt growth rate surpasses 96.72% of about US stocks.
  • The volatility of Adverum Biotechnologies Inc's share price is greater than that of 99.6% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Adverum Biotechnologies Inc, a group of peers worth examining would be CYCN, CLSN, ABEO, QUIK, and HRTX.
  • Visit ADVM's SEC page to see the company's official filings. To visit the company's web site, go to www.adverum.com.

ADVM Valuation Summary

  • In comparison to the median Healthcare stock, ADVM's price/sales ratio is 736.84% higher, now standing at 31.8.
  • Over the past 86 months, ADVM's EV/EBIT ratio has gone up 49.6.
  • ADVM's EV/EBIT ratio has moved up 49.6 over the prior 86 months.

Below are key valuation metrics over time for ADVM.

Stock Date P/S P/B P/E EV/EBIT
ADVM 2021-08-31 31.8 0.6 -1.7 -2.3
ADVM 2021-08-30 31.3 0.6 -1.7 -2.2
ADVM 2021-08-27 31.4 0.6 -1.7 -2.2
ADVM 2021-08-26 30.1 0.6 -1.6 -2.2
ADVM 2021-08-25 31.4 0.6 -1.7 -2.2
ADVM 2021-08-24 30.7 0.6 -1.7 -2.2

ADVM Growth Metrics

  • The 3 year price growth rate now stands at 55.07%.
  • Its 5 year net cashflow from operations growth rate is now at -40.27%.
  • Its 4 year cash and equivalents growth rate is now at -46.92%.
ADVM's revenue has moved up $5,888,000 over the prior 33 months.

The table below shows ADVM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 7.5 -104.24 -148.763
2021-06-30 7.5 -104.988 -138.17
2021-03-31 7.5 -87.98 -123.037
2020-12-31 0 -79.291 -117.507
2020-09-30 0 -71.902 -98.8
2020-06-30 0.25 -54.888 -87.149

ADVM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ADVM has a Quality Grade of C, ranking ahead of 36.31% of graded US stocks.
  • ADVM's asset turnover comes in at 0.015 -- ranking 380th of 682 Pharmaceutical Products stocks.
  • REGN, PRGO, and ORMP are the stocks whose asset turnover ratios are most correlated with ADVM.

The table below shows ADVM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.015 1 -0.294
2021-03-31 0.017 1 -0.306
2020-12-31 0.000 NA -0.331
2020-09-30 0.000 NA -0.345
2020-06-30 0.001 1 -0.416
2020-03-31 0.001 1 -0.447

ADVM Price Target

For more insight on analysts targets of ADVM, see our ADVM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $3.57 Average Broker Recommendation 1.94 (Hold)

ADVM Stock Price Chart Interactive Chart >

Price chart for ADVM

ADVM Price/Volume Stats

Current price $1.94 52-week high $14.79
Prev. close $2.03 52-week low $1.89
Day low $1.89 Volume 727,900
Day high $1.99 Avg. volume 1,978,570
50-day MA $2.15 Dividend yield N/A
200-day MA $4.82 Market Cap 190.41M

Adverum Biotechnologies, Inc. (ADVM) Company Bio


Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company was founded in 2006 and is based in Menlo Park, California.


ADVM Latest News Stream


Event/Time News Detail
Loading, please wait...

ADVM Latest Social Stream


Loading social stream, please wait...

View Full ADVM Social Stream

Latest ADVM News From Around the Web

Below are the latest news stories about Adverum Biotechnologies Inc that investors may wish to consider to help them evaluate ADVM as an investment opportunity.

Adverum Reports Third Quarter 2021 Results

REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the third quarter ending September 30, 2021 and provided a business update. “Last month we presented new data at scientific meetings from both our OPTIC and INFINITY studies which reinforce our plans to focus the development of ADVM-022 in wet age-related macular

Yahoo | November 4, 2021

Does Adverum Biotechnologies Inc. (NASDAQ:ADVM) Look Expensive At $2.00? Here’s How To Know.

In last trading session, Adverum Biotechnologies Inc. (NASDAQ:ADVM) saw 1.09 million shares changing hands with its beta currently measuring 1.10. Company’s recent per share price level of $2.00 trading at -$0.01 or -0.50% at ring of the bell on the day assigns it a market valuation of $203.88M. That closing price of ADVM’s stock is … Does Adverum Biotechnologies Inc. (NASDAQ:ADVM) Look Expensive At $2.00? Here’s How To Know. Read More »

Marketing Sentinel | October 22, 2021

Analysts Expect Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Will Post Earnings of -$0.40 Per Share

Equities analysts expect Adverum Biotechnologies, Inc. (NASDAQ:ADVM) to report earnings per share (EPS) of ($0.40) for the current quarter, Zacks reports. Zero analysts have made estimates for Adverum Biotechnologies earnings. The lowest EPS estimate is ($0.46) and the highest is ($0.32). Adverum Biotechnologies reported earnings of ($0.31) per share during the same quarter last year, []

Dakota Financial News | October 22, 2021

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Shares Sold by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC cut its holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) by 13.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,950,000 shares of the biotechnology companys stock after selling 1,050,000 shares during the period. Avoro Capital Advisors LLC owned 0.07% of Adverum Biotechnologies []

Transcript Daily | October 20, 2021

Medical sectors Adverum Biotechnologiess (NASDAQ:ADVM) Hold rating Reiterated by SVB Leerink LLC 4 stars

Adverum Biotechnologies (NASDAQ:ADVM)s stock had its Hold rating Reiterated by by analysts at N/A in a research report issued to clients and investors. The post Medical sectors Adverum Biotechnologiess (NASDAQ:ADVM) Hold rating Reiterated by SVB Leerink LLC 4 stars appeared first on .

Stock Market Daily | October 12, 2021

Read More 'ADVM' Stories Here

ADVM Price Returns

1-mo -14.54%
3-mo -20.16%
6-mo -43.44%
1-year -86.24%
3-year -45.96%
5-year -31.93%
YTD -82.10%
2020 -5.90%
2019 265.71%
2018 -10.00%
2017 20.69%
2016 -69.54%

Continue Researching ADVM

Here are a few links from around the web to help you further your research on Adverum Biotechnologies Inc's stock as an investment opportunity:

Adverum Biotechnologies Inc (ADVM) Stock Price | Nasdaq
Adverum Biotechnologies Inc (ADVM) Stock Quote, History and News - Yahoo Finance
Adverum Biotechnologies Inc (ADVM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9253 seconds.